|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15511552155315541555155615571558155915601561...15771578» |
- || Enrollment change: The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=144, Completed, Sponsor: Seoul National University Hospital
N=192 --> 144
- ||| Trial completion: The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=144, Completed, Sponsor: Seoul National University Hospital
N=192 --> 144 Recruiting --> Completed
- Enrollment open: HYPROSAR: Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2014
P1/2, N=26, Recruiting, Sponsor: Kantonsspital Aarau
Recruiting --> Completed Not yet recruiting --> Recruiting
- | indoximod (NLG8189) / Lumos Pharma
Enrollment open: Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors (clinicaltrials.gov) - Mar 10, 2014
P1/2, N=18, Recruiting, Sponsor: NewLink Genetics Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment closed: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Mar 9, 2014
P2, N=37, Active, not recruiting, Sponsor: Italian Sarcoma Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | imatinib / Generic mfg.
Enrollment closed: Study to Evaluate Imatinib in Desmoid Tumors (clinicaltrials.gov) - Mar 9, 2014
P2, N=40, Active, not recruiting, Sponsor: Heidelberg University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- imetelstat (GRN163L) / Geron
Trial withdrawal: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- imetelstat (GRN163L) / Geron
Enrollment change: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Withdrawn N=110 --> 0
- Enrollment closed: ProAcTyon: Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Centre Oscar Lambret
N=110 --> 0 Recruiting --> Active, not recruiting
- Enrollment closed: Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 5, 2014
P2, N=240, Active, not recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 5, 2014
P3, N=620, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery, Metastases: ANGIO-TAX+: Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas (clinicaltrials.gov) - Mar 5, 2014
P2, N=70, Active, not recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Enrollment closed: Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Mar 5, 2014
P3, N=390, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- carboplatin / Generic mfg.
Trial completion: Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors (clinicaltrials.gov) - Mar 5, 2014
P2, N=41, Completed, Sponsor: AGO Study Group
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | aldoxorubicin (INNO-206) / ImmunityBio
Enrollment open: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma (clinicaltrials.gov) - Mar 4, 2014
P2, N=30, Recruiting, Sponsor: CytRx
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change: Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=132 --> 51
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma (clinicaltrials.gov) - Mar 4, 2014
P=N/A, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=132 --> 51 Suspended --> Active, not recruiting
- New P1 trial: MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors (clinicaltrials.gov) - Mar 2, 2014
P1, N=14, Not yet recruiting, Sponsor: Children's Research Institute
- | Fibromun (onfekafusp alfa) / Philogen
New P1 trial, Combination therapy, Metastases: L19TNF? in Combination With Doxorubicin in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Feb 28, 2014
P1, N=28, Recruiting, Sponsor: Philogen S.p.A.
- ||| Tibsovo (ivosidenib) / Servier
New P1 trial, Metastases: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation (clinicaltrials.gov) - Feb 26, 2014
P1, N=51, Recruiting, Sponsor: Agios Pharmaceuticals, Inc.
- Enrollment change: Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=781, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Suspended --> Active, not recruiting N=410 --> 781
- Enrollment change, Metastases: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=249, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=410 --> 781 N=200 --> 249
- Enrollment closed, Metastases: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=249, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=200 --> 249 Recruiting --> Active, not recruiting
- | motesanib (AMG 706) / Takeda
Trial completion, Stroma, Metastases: Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 25, 2014
P2, N=35, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Tasigna (nilotinib) / Novartis, Inhibikase
Trial termination, Stroma, Metastases: MACS0375: Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (clinicaltrials.gov) - Feb 24, 2014
P3, N=94, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Completed --> Terminated
- ||| telaglenastat (CB-839) / Calithera
New P1 trial, Combination therapy, Metastases: Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (clinicaltrials.gov) - Feb 24, 2014
P1, N=100, Recruiting, Sponsor: Calithera Biosciences, Inc
- Enrollment change: Spectroscopy With Surface Coils and Decoupling (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=582, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Terminated N=900 --> 582
- Trial completion: Spectroscopy With Surface Coils and Decoupling (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=582, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=900 --> 582 Recruiting --> Completed
- | topotecan / Generic mfg., carboplatin / Generic mfg.
Trial completion, Metastases: a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4 (clinicaltrials.gov) - Feb 22, 2014
P2, N=90, Completed, Sponsor: Cooperative Weichteilsarkom Study Group
Recruiting --> Completed Recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion: Imatinib in Dermatofibrosarcoma Protuberans (DFSP) (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=30, Completed, Sponsor: Dermatologic Cooperative Oncology Group
Recruiting --> Completed No longer recruiting --> Completed
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion, Stroma, Metastases: PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib (clinicaltrials.gov) - Feb 22, 2014
P2, N=45, Completed, Sponsor: Helsinki University
No longer recruiting --> Completed Recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion, Stroma: CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Feb 22, 2014
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | perifosine (D21266) / AEterna Zentaris
Trial completion, Metastases: Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| thrombospondin-1 mimetic (ABT-510) / AbbVie
Trial completion, Metastases: Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=88, Completed, Sponsor: Abbott
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=20169, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | Neutrexin (trimetrexate) / Pfizer
Trial completion: Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=18, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed Active, not recruiting --> Completed
- | melphalan / Generic mfg., busulfan / Generic mfg., cyclosporine / Generic mfg.
Trial completion: Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=10, Completed, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Trial completion, Metastases: Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Gynecologic Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
Trial completion: Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion: Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=70, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | oxaliplatin / Generic mfg.
Trial completion: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (clinicaltrials.gov) - Feb 22, 2014
P2, N=180, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| elesclomol (STA-4783) / Madrigal Pharma
Trial completion, Combination therapy: A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Feb 22, 2014
P2, N=80, Completed, Sponsor: Synta Pharmaceuticals Corp.
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Istodax (romidepsin) / Astellas, BMS
Trial completion: FR901228 in Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) (clinicaltrials.gov) - Feb 22, 2014
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- | temozolomide / Generic mfg., erlotinib / Generic mfg.
Trial completion: Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=95, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Dana-Farber Cancer Institute
No longer recruiting --> Completed Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=39, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed